Core Insights - Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on oncology, specifically targeting solid tumor cancers with the mutated KRAS oncogene [3]. Group 1: Company Presentation - Silexion management will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 3, 2025, from 2:30 to 2:55 PM ET [2]. - The presentation will be led by Ilan Hadar, CEO, and Mirit Horenshtein-Hadar, CFO, at Florida Atlantic University Conference Center, Boca Raton, FL [2]. - Management will be available for one-on-one meetings during the conference, and interested parties can arrange meetings through their conference representative [2]. Group 2: Clinical Development - Silexion is dedicated to developing innovative treatments for solid tumor cancers, particularly those with the mutated KRAS oncogene, which is the most common oncogenic gene driver in human cancers [3]. - The company has conducted a Phase 2a clinical trial for its first-generation product, which showed a positive trend compared to chemotherapy alone [3]. - Silexion is focused on advancing its lead product candidate for locally advanced pancreatic cancer [3].

Core Viewpoint - OBOOK Holdings Inc. (OwlTing) has authorized a share repurchase program of up to USD $10 million, reflecting the Board's belief that the current market valuation does not fully represent the company's strengths and upcoming catalysts in its payment technology pipeline [1][2]. Share Repurchase Program - The repurchase program is effective for nine months and allows the company to buy back shares through various methods, including open-market purchases and block trades, in compliance with applicable securities laws [2][4]. - The company is not obligated to repurchase a specific number of shares, and the program may be modified or terminated based on market conditions or corporate needs [5]. Strategic Roadmap - OwlTing is set to launch transformative technologies that integrate traditional financial systems, stablecoin settlements, and AI-driven payment models, positioning itself as a critical infrastructure provider for digital currency adoption [3]. - Key anticipated milestones include the integration with a major global card network for seamless digital currency settlement, the implementation of stablecoin-based settlement architecture, and the deployment of an AI-driven autonomous settlement engine [7]. Company Overview - OBOOK Holdings Inc. operates as OwlTing Group, headquartered in Taiwan, with subsidiaries in multiple countries, and is recognized as a top player in the "Enterprise & B2B" category of the stablecoin market [6]. - The company's mission is to leverage blockchain technology for reliable data management and to facilitate the digital transformation of business operations, exemplified by its hybrid payment solution, OwlPay [6].

New York, Nov. 26, 2025 (GLOBE NEWSWIRE) -- CHIJET MOTOR COMPANY, INC. (NASDAQ: CJET) (“Chijet” or the “Company”), a global automotive technology enterprise, today announced that its digital asset treasury holdings have surpassed $400 million in value. The Company has acquired 100 million tokens as part of its strategic digital asset initiative announced earlier this month, with current holdings valued at over $400 million. “Reaching $400 million in digital asset treasury value represents an important miles ...

Core Insights - Celcuity Inc. is participating in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Miami, Florida [1] - CEO Brian Sullivan will have a fireside chat on December 3, 2025, at 7:30 a.m. ET, with a live webcast available [2] Company Overview - Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications [3] - The lead therapeutic candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor that blocks the PI3K/AKT/mTor pathway [3] - Ongoing clinical trials include VIKTORIA-1, which has completed enrollment for both PIK3CA wild-type and mutant cohorts, and VIKTORIA-2, which is currently enrolling patients [3] - A Phase 1/2 trial, CELC-G-201, is evaluating gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer [3]

Company Overview - USA Rare Earth, Inc. is developing a rare earth sintered neo magnet manufacturing plant in Stillwater, Oklahoma, aiming to establish domestic supply, extraction, and processing capabilities for rare earth and critical minerals [3] - The company intends to supply its magnet manufacturing plant and market surplus materials to third parties, focusing on various industries including defense, automotive, aviation, industrial, AI robotics, medical, and consumer electronics [3] - USA Rare Earth's strategy aligns with national priorities, offering the potential for a sustainable and secure domestic supply of materials critical to key industries [3] Index Inclusion - USA Rare Earth has been included on the preliminary list for addition to the Russell 2000 Index, with expected effectiveness on December 22, 2025, pending FTSE Russell's standard review process [1] - Membership in the Russell 2000 Index ensures automatic inclusion in the broader Russell 3000 Index and applicable growth and value style indexes, which are widely used by investment managers and institutional investors [2]

Core Insights - Calian Group Ltd. reported a significant turnaround in Q4 2025, with revenues increasing by 12%, attributed to a balanced mix of 6% organic growth and 6% from acquisitions [2][9] - The company achieved a 15% growth in its defence solutions segment, indicating strong performance in its core business areas [2][6] - For the full fiscal year 2025, Calian maintained a double-digit adjusted EBITDA margin of 10.1%, despite a 15% decline in adjusted EBITDA primarily due to the performance of the ITCS segment [3][5] Financial Highlights - Q4 2025 revenues reached $203.2 million, up from $181.2 million in Q4 2024, marking a 12% increase [5][9] - Full year revenues for 2025 totaled $774.1 million, a 4% increase from $746.6 million in 2024 [5][6] - Adjusted EBITDA for Q4 2025 was $24.3 million, a 2% increase year-over-year, with an adjusted EBITDA margin of 11.9% [5][10] - The adjusted net profit for Q4 2025 was $11.5 million, or $1.00 per diluted share, reflecting a 10% increase from $10.5 million, or $0.87 per diluted share, in Q4 2024 [5][11] Operational Developments - The company has a robust backlog of $1.4 billion, which positions it well for growth in fiscal year 2026 [4][12] - Calian launched Calian VENTURES to support the growth of Canadian Defence SMEs and partners, indicating a strategic focus on enhancing its defence capabilities [17] - The acquisition of InField Scientific, completed in October 2025, expands Calian's defence portfolio and enhances its electromagnetic solutions capabilities [15] Debt and Cash Flow - Calian renewed and expanded its debt agreement to a total of $350 million, providing financial flexibility for future investments [16] - Operating free cash flow for Q4 2025 was $17 million, representing a conversion rate of 72% [6][35] - The net debt to adjusted EBITDA ratio stood at 1.1x as of September 30, 2025, indicating a manageable level of debt relative to earnings [36]

Core Viewpoint - Currency Exchange International, Corp. has received approval from the Toronto Stock Exchange to renew its normal course issuer bid (NCIB) and Automatic Securities Purchase Plan (ASPP) to repurchase up to 359,617 common shares, representing 10% of the public float as of November 18, 2025 [1][2]. Group 1: NCIB Details - The NCIB will allow the company to repurchase shares starting from December 2, 2025, until December 1, 2026, or earlier if the maximum number of shares is repurchased [2]. - The company has 6,134,120 common shares outstanding as of November 18, 2025, and will purchase shares on the open market at prevailing market rates [2][3]. - The average daily trading volume for the common shares on the TSX was 3,908, allowing a maximum repurchase of 1,000 shares per trading day under TSX policies [4]. Group 2: Rationale for Share Repurchase - The Group CEO and Board of Directors believe that the market price may not reflect the underlying value of the company, and repurchasing shares can enhance shareholder value during periods of volatility [5]. - The previous NCIB allowed the company to repurchase 323,500 shares at an average price of C$21.30, indicating a proactive approach to managing share value [6]. Group 3: ASPP Implementation - The company has established an ASPP with its broker for automatic share purchases under the NCIB, effective December 2, 2025 [7]. - All repurchases made under the ASPP will count towards the total shares purchased under the NCIB [7]. Group 4: Company Overview - Currency Exchange International, Corp. provides foreign exchange technology and processing services for banks, credit unions, businesses, and consumers, with a focus on foreign currency exchange, wire transfers, and cheque clearing [8].

Core Insights - CG Oncology has appointed Christina Rossi, an experienced life sciences executive, to its Board of Directors, while Simone Song has resigned from the Board [1][2] - The company is at a pivotal moment with the initiation of the Biologics License Application (BLA) for cretostimogene, aiming for a successful launch upon FDA approval [2] - Cretostimogene is an investigational oncolytic immunotherapy being studied in over 400 patients with Non-Muscle Invasive Bladder Cancer (NMIBC) through multiple clinical trials [4] Company Overview - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing a bladder-sparing therapeutic for bladder cancer patients [5] - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [5] Executive Background - Christina Rossi has over 25 years of experience in the pharmaceutical and biotechnology sectors, previously serving as COO of Blueprint Medicines and holding various leadership roles at Sanofi Genzyme and Biogen [3] - Rossi's expertise includes overseeing commercial launches and optimizing operations to improve patient access to therapies [3]

Core Insights - Can-Fite BioPharma Ltd. is advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, with CEO Motti Farbstein scheduled to present at NobleCon21 on December 3, 2025 [1][2] Company Overview - Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology aimed at addressing multi-billion-dollar markets in cancer, liver, and inflammatory disease treatment [4] - The lead drug candidate, Piclidenoson, has reported topline results in a Phase III trial for psoriasis and has commenced a pivotal Phase III trial [4] - The liver drug, Namodenoson, is being evaluated in multiple trials, including a Phase III trial for hepatocellular carcinoma (HCC) and has received Orphan Drug Designation and Fast Track Designation from the U.S. FDA [4] - CF602, the third drug candidate, has shown efficacy in treating erectile dysfunction, with all drugs demonstrating an excellent safety profile in over 1,600 patients [4] Financial Agreements - Can-Fite has secured numerous out-licensing and global distribution agreements valued at up to $130 million for pharmaceutical indications and an additional up to $325 million for veterinary indications [2]

Core Insights - Herantis Pharma has successfully completed a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096, demonstrating a favorable safety and tolerability profile, which supports its advancement towards a Phase 2 clinical efficacy trial [1][2] - The completion of the toxicology study is a significant milestone in the HER-096 program, providing a strong foundation for further clinical development following positive results from the Phase 1b trial [2][3] - HER-096 is a first-in-class small peptide designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF), with the potential to stop the progression of Parkinson's disease and improve patients' quality of life [5][8] Preclinical and Clinical Development - The preclinical toxicology study results align with previous preclinical and clinical data, reinforcing confidence in HER-096's long-term administration suitability [1][2] - The Phase 1b trial of HER-096 met all primary and secondary endpoints, with pharmacokinetic data consistent with healthy volunteers and confirmed efficient brain penetration [3][4] - Herantis plans to initiate a Phase 2 clinical trial in 2026 to evaluate the efficacy, safety, and tolerability of HER-096 in early-stage Parkinson's patients [4][8] Funding and Support - The completion of the preclinical toxicology program marks the final milestone of the EIC Accelerator Grant project, which provided EUR 2.5 million to support the development of HER-096 and its biomarker program [2][3] - The biomarker development results have already been applied in exploratory analyses within the Phase 1b clinical trial, enhancing the overall research framework [2][3] Mechanism of Action - HER-096 operates through a multimodal mechanism targeting key drivers of neurodegeneration in Parkinson's disease, including modulation of the Unfolded Protein Response (UPR) pathway and reduction of neurotoxic protein aggregation [6][7] - The compound has shown compelling preclinical results, demonstrating its neurorestorative potential and favorable safety profile following subcutaneous administration [7][8]